Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
"The World's Most Prevalent Sexually-Transmitted Bacteria
Phase II STTR from the National Institute of Allergy and Infectious Diseases
IRVINE, Calif., Sept. 21 /PRNewswire/ -- Antigen Discovery, Inc. ('ADi', formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009"
Phase II STTR from the National Institute of Allergy and Infectious Diseases
IRVINE, Calif., Sept. 21 /PRNewswire/ -- Antigen Discovery, Inc. ('ADi', formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009"
posted by blog manager at
8:39 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home